Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies
Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2015.02.018
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2015
Authors
Publisher
Elsevier BV